Drugdocs | Entresto

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Entresto

Chemical Name	sacubitril/valsartan
Dosage Form	Tablet (oral; sacubitril mg/ valsartan mg: 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg)
Drug Class	Inhibitors
System	Cardiovascular
Company	Novartis
Approval Year	2015

Indication

To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Entresto (sacubitril and valsartan) Prescribing Information	2019	Novartis Pharmaceuticals Corporation, East Hanover, NJ

Document Title	Year	Source
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction.	2016	NICE
Sacubitril-valsartan (Entresto) for heart failure.	2016	HAYES Inc.